Toremifene – a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

Author： Taneja Samir S   Smith Matthew R   Dalton James T   Raghow Sharan   Barnette Gary   Steiner Mitchell   Veverka Karen A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.15, Iss.3, 2006-03, pp. : 293-305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Androgen deprivation therapy for prostate cancer

By Singer Eric A   Golijanin Dragan J   Miyamoto Hiroshi   Messing Edward M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 2, 2008-02 ,pp. : 211-228

Informa Healthcare

Access to resources Recommend Favorite

Toremifene a strong option in androgen-deprivation therapy

By  

Inpharma, Vol. 1, Iss. 1635, 2008-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

Bisphosphonates to Prevent Osteoporosis in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

By Smith M.R.  

Drugs & Aging, Vol. 20, Iss. 3, 2003-01 ,pp. : 175-183

Adis International

Access to resources Recommend Favorite

Management of the side effects of androgen deprivation therapy in men with prostate cancer

By Flaig Thomas W   Glodé L Michael  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2829-2841

Informa Healthcare

Access to resources Recommend Favorite

The Role of Intracrine Androgen Metabolism, Androgen Receptor and Apoptosis in the Survival and Recurrence of Prostate Cancer During Androgen Deprivation Therapy

By  

Current Drug Targets, Vol. 14, Iss. 4, 2013-04 ,pp. : 420-440

Bentham Science Publishers

Access to resources Recommend Favorite